Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALBIREO PHARMA, INC.

(ALBO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Albireo Pharma Swings to Q3 Gain on Sale of Priority Review Voucher; Shares Fall

11/04/2021 | 11:04am EST


ę MT Newswires 2021
All news about ALBIREO PHARMA, INC.
01/06Albireo Increases 2021 Bylvay (odevixibat) Sales Guidance
AQ
01/05ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K/A
PU
01/05ALBIREO PHARMA, INC. Results of Operations and Financial Condition, Change in Director..
AQ
01/05Albireo Increases 2021 Bylvay™á(odevixibat) Sales Guidance
AQ
01/05Albireo Pharma, Inc. Provides Sales Guidance for the Full Year of 2021
CI
01/05ALBIREO PHARMA, INC. : Results of Operations and Financial Condition, Change in Directors ..
AQ
01/05ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K
PU
01/05Albireo Pharma, Inc. Announces Resignation of Roger A. Jeffs as Independent Director
CI
01/03Immix Biopharma Shares More Than Double on FDA Designation
DJ
2021Albireo Pharma's Early Stage Trial Confirms Safety, Tolerability of Liver Disease Drug
MT
More news
Analyst Recommendations on ALBIREO PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 14,8 M - -
Net income 2021 -69,0 M - -
Net cash 2021 209 M - -
P/E ratio 2021 -7,33x
Yield 2021 -
Capitalization 505 M 505 M -
EV / Sales 2021 19,9x
EV / Sales 2022 7,36x
Nbr of Employees 90
Free-Float 87,2%
Chart ALBIREO PHARMA, INC.
Duration : Period :
Albireo Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALBIREO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 26,17 $
Average target price 73,33 $
Spread / Average Target 180%
EPS Revisions
Managers and Directors
Ronald H. W. Cooper President, Chief Executive Officer & Director
Simon John Harford Chief Financial Officer & Treasurer
David John Chiswell Chairman
Jan Peter Mattsson Chief Scientific Officer, Managing Director-Sweden
Joan Connolly Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ALBIREO PHARMA, INC.12.37%505
GILEAD SCIENCES, INC.-5.56%86 013
REGENERON PHARMACEUTICALS-1.60%64 979
VERTEX PHARMACEUTICALS4.59%58 397
WUXI APPTEC CO., LTD.-5.63%51 604
BIONTECH SE-41.44%36 465